Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid dosing intervals in metastatic cancer
NCT00869206Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2009
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer, prostate cancer (PCa) and multiple myeloma (MM), sponsored by Cancer and Leukemia Group B. Primary endpoint: Percentage of Participants With at Least One Skeletal-related Event at 2 years. Started Mar 2009; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancerprostate cancer (PCa)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00869206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869206.